CareDx, Inc.

CareDx reports that substantially all of its revenue comes from the United States and Europe, with assets and operations concentrated in the United States and Sweden. The company’s headquarters are in Brisbane, California, and it has primary operations in Omaha, Nebraska and Stockholm, Sweden. This footprint matters because the business depends on regulated clinical testing, reimbursement systems, and data handling across multiple jurisdictions. Foreign operations also create exposure to currency, regulatory, and cross-border compliance issues, even though the company notes that its foreign countries are economically stable. The geographic mix is important operationally because the company’s transplant-center relationships and laboratory capabilities are anchored in a few specialized hubs rather than a broad retail-style network.

CareDx faces reimbursement and billing risk because a large share of testing revenue depends on payer coverage policies, appeals processes, and healthcare reimbursement decisions. Regulatory risk is also material because the company operates clinical laboratories and must comply with CLIA, FDA-related rules, and fraud-and-abuse laws. The business depends on licensed technologies and intellectual property, so loss of key licenses or weak patent protection could impair product sales and competitive position. Cybersecurity and data privacy are important because the company stores protected health information, billing data, and proprietary operational data across on-site and cloud environments. More broadly, demand can fluctuate with transplant volumes, economic conditions, and the pace of commercialization of new products, while competition from large diagnostics companies and in-house lab solutions can pressure adoption.